Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04072315 · ClinicalTrials.gov registry record · Phase 2
Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/
A Phase 2 study of Idiopathic Pulmonary Fibrosis, sponsored by Pliant Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT04072315: Completed Phase 2 study of Idiopathic Pulmonary Fibrosis, sponsored by Pliant Therapeutics.
NCT04072315 is a Phase 2 study of Idiopathic Pulmonary Fibrosis that has completed, run by Pliant Therapeutics. The registered enrollment target is 9 participants, below the 751-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04072315, a Phase 2 study of Idiopathic Pulmonary Fibrosis, has completed, sponsored by Pliant Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
A study in mild/moderate IPF patients using an αVβ6 PET ligand to evaluate target engagement.
Primary Outcome
Assessment of the primary endpoint was made using standard methods for quantifying the amount to PET tracer bound to the αvβ6 integrin receptor in the lungs before and after administration of study drug and PK/PD modeling.
Conditions Studied
Interventions
- DRUG PLN-74809
- RADIATION Knottin tracer
Study Locations (1)
California
- Stanford Medical Center - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-02-13 |
| Est. Completion | 2022-07-05 |
| Phase | Phase 2 |
What the finished NCT04072315 record still lists
NCT04072315 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 751-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which PLN-74809 is the first listed.
NCT04072315 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04072315 about?
NCT04072315 is a clinical study titled "Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/". A study in mild/moderate IPF patients using an αVβ6 PET ligand to evaluate target engagement.
What is the current status of trial NCT04072315?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2020-02-13. Estimated completion is 2022-07-05.
What conditions does trial NCT04072315 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis.
What interventions are being tested in trial NCT04072315?
The interventions under investigation include: PLN-74809 (DRUG), Knottin tracer (RADIATION).
Who is sponsoring clinical trial NCT04072315?
This trial is sponsored by Pliant Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04072315 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04072315's enrollment target sits among peer trials
9 50th of 51 higher than 2 of 51 other Idiopathic Pulmonary Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Idiopathic Pulmonary Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
RECRUITING · Phase 2
-
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
RECRUITING · Phase 2
-
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
RECRUITING · Phase 2
-
H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI